Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function

被引：0
作者：
Ebina, M.
Kimura, Y.
Ohta, H.
Hisata, S.
Tamada, T.
Nukiwa, T.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2010年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3988
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Factors influencing Idiopathic Pulmonary Fibrosis (IPF) anti-fibrotic decisions in a single UK centre; patient and physician perspectives
    Papadopoulos, Alexis
    Zannetos, Savvas
    Hoyles, Rachel
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [32] A HUMAN MODEL OF LUNG FIBROSIS FOR THE ASSESSMENT OF ANTI-FIBROTIC STRATEGIES IN IDIOPATHIC PULMONARY FIBROSIS
    Roach, K. M.
    Tongue, P.
    Castells, E.
    Elliot, G.
    Marshall, H.
    Richardson, M.
    Mason, S.
    Chachi, L.
    Bradding, P.
    THORAX, 2019, 74 : A56 - A57
  • [33] Pro-fibrotic Factors as Potential Biomarkers of Anti-fibrotic Drug Therapy in Patients With Idiopathic Pulmonary Fibrosis
    Lopez-Lopez, Lidia
    Cesar, Eva Cabrera
    Lara, Estrella
    Juan, M. Victoria Hidalgo-San
    Parrado, Concepcion
    Martin-Montanez, Elisa
    Garcia-Fernandez, Maria
    ARCHIVOS DE BRONCONEUMOLOGIA, 2021, 57 (03): : 231 - 233
  • [34] Real-life survival of idiopathic pulmonary fibrosis with anti-fibrotic medication
    Bleinc, Alexandre
    Blin, Timothee
    Legue, Sylvie
    Mankikian, Julie
    Plantier, Laurent
    Marchand-Adam, Sylvain
    REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (05) : 371 - 381
  • [35] Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world
    Sugimoto, Chikatoshi
    Inoue, Yoshikazu
    Arai, Toru
    Kasai, Takehiko
    Akira, Masanori
    Hayashi, Seiji
    Tachibana, Kazunobu
    Sasaki, Yumiko
    Takeuchi, Naoko
    Minomo, Syojiro
    Ikegami, Naoya
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [36] Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
    Leuschner, Gabriela
    Stocker, Florian
    Veit, Tobias
    Kneidinger, Nikolaus
    Winter, Hauke
    Schramm, Rene
    Weig, Thomas
    Matthes, Sandhya
    Ceelen, Felix
    Arnold, Paola
    Munker, Dieter
    Klenner, Friederike
    Hatz, Rudolf
    Frankenberger, Marion
    Behr, Juergen
    Neurohr, Claus
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (02) : 268 - 274
  • [37] Anti-Fibrotic Therapy for Idiopathic Pulmonary Fibrosis Is Associated with Decreased Mortality Among Hospitalized Patients
    Kelly, B.
    Thao, V.
    Dempsey, T. M.
    Sangaralingham, L.
    Payne, S.
    Limper, A. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [38] Real-World Tolerability Of Anti-Fibrotic Therapy For Idiopathic Pulmonary Fibrosis
    Kaur, R.
    King, C.
    Brown, A.
    Shlobin, O.
    Ahmad, S.
    Weir, N.
    Nathan, S. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [39] Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
    Khor, Yet H.
    Ng, Yvonne
    Barnes, Hayley
    Goh, Nicole S. L.
    McDonald, Christine F.
    Holland, Anne E.
    EUROPEAN RESPIRATORY REVIEW, 2020, 29 (157) : 1 - 16
  • [40] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin E.
    Zhong, Jun
    Papakonstantinou, Eleni
    Karakiulakis, George
    Tamm, Michael
    Seidel, Petra
    Sun, Qingzhu
    Mandal, Jyotshna
    Lardinois, Didier
    Lambers, Christopher
    Roth, Michael
    RESPIRATORY RESEARCH, 2014, 15
12345